Veru Stock News

--Planned Conditional Statistical Power Analysis was Conducted—

Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,

Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

--FC2 Prescription Business Entering 6th Year of Growth -- --FDA Approves Company’s ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway--

--FC2 Prescription Business Entering 6 th Year of Growth -- --FDA Approves Company’s ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway--

Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell Equinor (NYSE: EQNR ) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. ICL Group (NYSE: ICL ) is expected to report quarterly earnings at $0.13 per share on revenue of $1.82 billion. Madison Square Garden (NYSE: MSGE ) is projected to report quarterly earnings at $1.00 per share on revenue of $538.98 million. Anavex Life Sciences (NASDAQ: AVXL ) is likely to report earnings for its first quarter. Orion Energy Sys (NASDAQ: OESX ) is likely to report quarterly earnings at $0.04 per share on revenue of $32.86 million. Penske Automotive Group (NYSE: PAG ) is estimated to report quarterly earnings at $3.69 per share on revenue of $6.22 billion. Mastech Digital (AMEX: MHH ) is projected to report quarterly earnings at $0.38 per share on revenue of $59.90 million. Perion Network (NASDAQ: PERI ) is projected to report quarterly earnings at $0.39 per share on revenue of $144.96 million. Ares Capital (NASDAQ: ARCC ) is estimated to report quarterly earnings at $0.49 per share on revenue of $459.14 million. Lithia Motors (NYSE: LAD ) is expected to report quarterly earnings at $10.14 per share on revenue of $6.15 billion. Cameco (NYSE: CCJ ) is expected to report quarterly earnings at $0.03 per share on revenue of $362.39 million. CDW (NASDAQ: CDW ) is expected to report quarterly earnings at $1.92 per share on revenue of $5.18 billion. Bunge (NYSE: BG ) is projected to report quarterly earnings at $2.55 per share on revenue of $13.61 billion. Yum Brands (NYSE: YUM ) is likely to report quarterly earnings at $1.09 per share on revenue of $1.88 billion. Crown Crafts (NASDAQ: CRWS ) is likely to report quarterly earnings at $0.24 per share on revenue of $18.80 million.

Veru (NASDAQ:VERU) is scheduled to announce FQ1 earnings results on Wednesday, February 9th, before market open.The consensus EPS Estimate is -$0.07 vs

The consensus price target hints at a 343.6% upside potential for Veru Inc. (VERU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

-- Phase 3 ENABLAR-2 Clinical Trial for 2nd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer Expected to Commence During First Quarter of 2022 -- MIAMI, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Veru

The FDA has granted Fast Track designation to Veru Inc''s (NASDAQ: VERU ) sabizabulin, oral cytoskeleton disruptor, to combat COVID-19 infection and the cytokine storm responsible for Acute Respiratory Distress Syndrome (ARDS) and death. Sabizabulin disrupts microtubule intracellular transport of the coronavirus, a process that new COVID-19 variants or strains will still require to cause infection. The Company notes that … Full story available on Benzinga.com